Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros

Base de dados
Tipo de estudo
Tipo de documento
Assunto da revista
Intervalo de ano de publicação
1.
J Med Chem ; 18(4): 383-5, 1975 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-1121005

RESUMO

Alkoxymethyl, acyloxymethyl, and mixed alkylalkoxymethyl or alkylacyloxymethyl derivatives of 5-ethyl-5-phenylhydantoin exhibit anticonvulsant activity. Also effective are bis(alkoxymethyl) and mixed alkylalkoxymethyl derivatives of 5,5-diphenylhydantoin. Of particular interest are 1,3-bis(methoxymethyl)-5,5-diphenylhydantoin and 3-acetoxymethyl-5-ethyl-5-phenylhydantoin, which show good activity against maximal electroshock seizures, and 3-methoxymethyl-5-ethyl-5-phenylhydantoin, which is effective against both maximal electroshock and pentylenetetrazole. None of the above compounds show greater activity against maximal electroshock seizures than the parent compounds, however.


Assuntos
Anticonvulsivantes/síntese química , Hidantoínas/síntese química , Fenitoína/análogos & derivados , Animais , Anticonvulsivantes/farmacologia , Anticonvulsivantes/toxicidade , Depressão Química , Eletrochoque , Hidantoínas/farmacologia , Hidantoínas/toxicidade , Dose Letal Mediana , Masculino , Camundongos , Atividade Motora/efeitos dos fármacos , Pentilenotetrazol/antagonistas & inibidores , Fenitoína/síntese química , Fenitoína/farmacologia , Fenitoína/toxicidade , Reflexo/efeitos dos fármacos , Convulsões/prevenção & controle , Sono/efeitos dos fármacos
2.
J Med Chem ; 18(7): 694-6, 1975 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-1151990

RESUMO

Several 1,3-disubstituted and 1-substituted derivatives of 5-propionoxy-5-(1-phenylethyl)barbituric acid were synthesized and evaluated for analgesic activity. Three of these compounds, 1,3-bis(methoxymethyl)-5-propionoxy-5-(1-phenylethyl)barbituric acid (2), 1,3-dimethyl-5-propionoxy-5-(1-phenylethyl)barbituric acid (7), and 1-methyl-5-propionoxy-5-(1-phenylethyl)barbituric acid (10), exhibited better oral activity than codeine sulfate.


Assuntos
Analgésicos/síntese química , Barbitúricos/síntese química , Analgésicos/farmacologia , Analgésicos/toxicidade , Animais , Barbitúricos/farmacologia , Barbitúricos/toxicidade , Sistema Nervoso Central/efeitos dos fármacos , Depressão Química , Dose Letal Mediana , Masculino , Camundongos , Estimulação Química
7.
J Am Acad Dermatol ; 7(6): 747-51, 1982 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-7174912

RESUMO

Two patients, who developed eczematous eruptions beneath Curad-brand medical adhesive plastic bandages, were found to have allergic contact dermatitis to N-dodecyl maleamic acid. N-dodecyl maleamic acid is a monomer used in the production of the adhesive in Curad bandages. Our patients were also sensitive to several closely related chemical compounds. We discuss the chemical requisite for allergenicity of these compounds. These are the first documented cases of allergic contact dermatitis from dodecyl maleamic acid.


Assuntos
Adesivos/efeitos adversos , Bandagens/efeitos adversos , Dermatite de Contato/etiologia , Maleatos/efeitos adversos , Adulto , Feminino , Humanos , Testes do Emplastro , Relação Estrutura-Atividade
8.
Calcif Tissue Int ; 44(1): 61-4, 1989 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-2521808

RESUMO

Thionapthene-2-carboxylic acid (TNCA) was previously shown to lower serum calcium concentrations in hypercalcemic rats: however, oral administration of TNCA may cause gastric irritation. We have assessed thionapthene-2-carboxylic acid lysine salt (TNLY) for its effects on serum calcium concentration and survival in rats bearing the hypercalcemic Leydig cell tumor. TNLY (0.6-1.8 mmol/kg/day) produced a marked and prolonged dose-related decrease in serum calcium concentration. At the highest dose of 1.8 mmol/kg/day, hypocalcemia occurred. Effects were sustained for 96 hours or longer. In tumor-bearing rats that were not yet hypercalcemic, pretreatment with TNLY (0.9 mmol/kg/day) did not induce hypocalcemia and the onset of hypercalcemia was prevented. Neither TNLY nor dichloromethylene diphosphonate (CL2MDP), a potent inhibitor of bone resorption, significantly prolonged overall survival. We concluded that TNLY is a potent antihypercalcemic agent that warrants further testing for use in the treatment of hypercalcemic disorders.


Assuntos
Hipercalcemia/tratamento farmacológico , Tumor de Células de Leydig/metabolismo , Lisina/análogos & derivados , Tiofenos/uso terapêutico , Animais , Reabsorção Óssea/efeitos dos fármacos , Cálcio/sangue , Ácido Clodrônico/farmacologia , Hipercalcemia/etiologia , Tumor de Células de Leydig/complicações , Lisina/farmacologia , Lisina/uso terapêutico , Masculino , Ratos , Ratos Endogâmicos F344 , Tiofenos/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA